Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2305]

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Trial argues strongly for the development of 1st-line biomarker selected...

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

ARV-766 well tolerated and shows promising clinical activity in metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2024: Latest in mRCC treatment

Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas...

ASCO 2024: Latest in mRCC treatment ( Dr Sumanta Kumar Pal, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Thomas Powles )

ASCO 2024: Advances in NSCLC

Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo

ASCO 2024: Advances in NSCLC ( Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Osimertinib success in locally advanced EGFR-mutated NSCLC

Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA

Osimertinib success in locally advanced EGFR-mutated NSCLC ( Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond...

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy ( Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China )

More from ecancer